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A b s t r a c t
Introduction: Mixed connective tissue disease (MCTD) is a  chronic im-
mune-mediated disorder defined by the combined presence of serum anti- 
RNP antibodies and distinct clinical features including progressive lung fi-
brosis. The aim of this study was to evaluate potential associations between 
lung fibrosis in MCTD and specific clinical and laboratory findings including 
results of nailfold capillaroscopy (NFC) examination. 
Material and methods: Patients with MCTD who were admitted to the De-
partments of Allergy and Immunology or Dermatology at the University Hos-
pital of Krakow (Poland) in 2015–2018 were identified based on compre-
hensive individual record review. Diagnosis of MCTD required fulfilment of 
at least one of the four widely accepted sets of diagnostic criteria. Clinical 
and laboratory data were collected, and statistical analysis was performed 
to identify potential predictors of interstitial lung disease (ILD). 
Results: Thirty patients (90% females) aged 22–81 years met the study in-
clusion criteria. The mean duration of symptoms associated with MCTD was 
7.3 months. Photosensitivity and Raynaud’s phenomenon were the most 
common clinical manifestations (90% and 70%, respectively). Hand oede-
ma, sclerodactyly and the presence of giant capillaries in NFC correlated 
significantly with the risk of lung involvement. In multivariate analysis, the 
presence of enlarged loops in NFC (giant capillaries) was identified as an 
independent factor for ILD (R2 = 0.82, p < 0.0000001).
Conclusions: The NFC examination should be considered in all patients with 
a diagnosis of MCTD. The presence of giant capillaries may be a promising 
marker for interstitial lung disease in these patients, especially among those 
with a short duration of disease (i.e. < 1 year). 
Key words: capillaroscopy, mixed connective tissue disease, interstitial 
lung disease.
Introduction
Mixed connective tissue disease (MCTD) is a  systemic autoimmune 
disease characterized by the presence of autoantibodies targeting the 
U1-RNP and the simultaneous presence of distinct clinical features (e.g. 
myositis, lung fibrosis, skin lesions) [1]. Morbidity and mortality in MCTD 
are driven mainly by lung involvement. A recent systematic evaluation of 
lung involvement among MCTD patients revealed at least one high res-
Rheumatology 
Magdalena Celińska-Löwenhoff, Maciej Pastuszczak, Karolina Pełka, Magdalena Stec-Polak, Anna Wojas-Pelc, Jacek Musiał
298 Arch Med Sci 2, February / 2020
olution computed tomography (HRCT) abnormality 
compatible with interstitial lung disease (ILD) in 
52% of included individuals [2]. In a separate study, 
severe lung fibrosis was found in 19% of patients 
with MCTD [3]. Moreover, patients with MCTD and 
severe lung fibrosis had almost seven times high-
er risk of death compared with those with normal 
HRCT scanning [2]. Recent studies showed that if 
left untreated, ILD in patients with MCTD progress-
es. However, progression of lung disease does not 
seem to be as rapid as can occur in systemic sclero-
sis or dermatomyositis/polymyositis [3]. 
Theoretically, early detection of lung involve-
ment and more aggressive treatment protocols 
may improve outcomes in patients with MCTD. 
Previous work has suggested that anti-Ro52 an-
tibodies may serve as a potential marker for lung 
fibrosis in MCTD [4]. Nailfold capillaroscopy (NFC) 
is a  non-invasive diagnostic tool for patients 
with different connective tissue diseases (CTDs) 
that permits the detection of local microvascu-
lar changes that correlate with systemic vascular 
involvement. Interestingly, structural abnormali-
ties in the capillary bed, found in NFC, very often 
precede the onset of systemic manifestations of 
CTDs. Therefore, the associations between HRCT 
abnormalities and some clinical features and re-
sults of nailfold capillaroscopy (NFC) were inves-
tigated in a well-defined MCTD cohort character-
ized by short disease duration (i.e. < 1 year). 
Material and methods
Study cohort
Hospital records from 179 patients who had at-
tended the Departments of Allergy and Immunol-
ogy or Dermatology at the University Hospital of 
Cracow (Poland) from 2015 to 2018 were reviewed 
to identify those diagnosed with MCTD (i.e. M35.1) 
by the ICD-10. Study inclusion criteria comprised: 
age ≥ 18 years, clinical diagnosis of MCTD, posi-
tive anti-RNP test, fulfilment of at least one of the 
criteria set for MCTD (i.e. the criteria of Sharp [5], 
Alarcon-Segovia and Villareal [6], Kasukawa [7], or 
Kahn and Appelboom [8]), exclusion of other con-
nective tissue diseases and a disease duration of 
no longer than one year. Additionally, only patients 
with complete HRCT scan data, laboratory results 
(complete blood count), autoantibody analyses and 
NFC at disease onset were included. Altogether, 
30 patients met the inclusion criteria and were en-
rolled in this study. 
Autoantibody analysis
Autoantibodies directed at various cellular 
compartments (including nuclear constituents, 
components of the nuclear envelope, mitotic spin-
dle apparatus, cytosol, cytoplasmic organelles and 
cell membranes) were tested by indirect immuno-
fluorescence (IIF) in the IgG isotype (HEp-20-10 
cells and the conjugate, Euroimmun, Lübeck, Ger-
many). Further identification of specific antibod-
ies was performed by immunoblot (ANA Profile 3 
Euroline Blot test kit; Euroimmun, Lübeck, Germa-
ny) according to the manufacturer’s instructions. 
With this test fifteen autoantibodies have been 
determined, i.e. antibodies against RNP, Sm, SS-A, 
Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, centromere pro-
tein B, PCNA, dsDNA, nucleosomes, histones, ribo-
somal P-proteins, AMA M2.
HRCT lung scans analysis 
The presence, extent and distribution of ground-
glass attenuations, airspace consolidation, retic-
ular patterns and interlobular septal thickening 
were evaluated according to the radiologic criteria 
of interstitial lung disease (ILD) recommended by 
the Nomenclature Committee of the Fleischner 
Society [9]. The extent of reticular patterns (i.e. 
the coarseness of the lung fibrosis) was assessed 
as the percentage of lung parenchyma involved 
with 1–14% being mild fibrosis, 15–49% moder-
ate fibrosis, and > 50% severe fibrosis. 
Pulmonary function tests
Pulmonary function tests (PFTs) performed in 
all MCTD patients included dynamic spirometry 
and carbon monoxide diffusion capacity. In ad-
dition, all patients underwent a 6-min walk test 
(6MWT). 
Nailfold capillaroscopy (NFC)
In all patients an NFC was performed before 
inclusion in the study, as described previously 
[10]. Briefly, field capillary microscopy with 100× 
magnification was used. Eight digits (excluding 
thumbs) were examined using a bifocal stereomi-
croscope. Immersion oil was applied to increase 
skin transparency and the whole nailfold region 
including the edges was examined. Abnormal 
findings were defined as enlargement of capil-
lary loops (giant capillaries; absolute number > 3), 
presence of bushy capillaries (> 1) and avascular 
areas (loss of two consecutive loops of nail bed). 
Statistical analysis 
Statistical analysis was carried out using Sta-
tistical 7.1 PL software (TIBCO Software Inc., Palo 
Alto, CA, USA). If not stated otherwise, data were 
expressed as median and minimum–maximum 
values. Continuous variables were compared with 
the Mann-Whitney U test. The c2 test or Fisher’s 
exact test was used for dichotomous variables. To 
identify independent factors, a multivariable logis-
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tic regression analysis was used. A p-value < 0.05 
was considered statistically significant. 
Results
Thirty patients (90% female) aged 22–81 years 
with MCTD were included in this study. Only two 
of them were ≥ 65 years. All patients fulfilled 
at least one of the MCTD criteria sets with 53% 
meeting the Sharp criteria, 47% the Alarcon-Sego-
via criteria, 90% the Kasukawa criteria, and 83% 
the Kahn criteria. The mean disease duration at 
the time of the study was 7.3 ±2 months. The 
most frequent symptoms at disease onset were 
photosensitivity (90%) and Raynaud’s phenome-
non (70%). Interstitial lung fibrosis was identified 
in 6 (20%) individuals and was defined as mild in 
all cases. None of the included patients had re-
spiratory symptoms such as breathlessness, chest 
discomfort or dry cough. The patients with fibrosis 
had non-significantly lower PFT values and 6MWT, 
and a higher WHO class than the individuals with 
normal HRCT. Clinical and laboratory characteris-
tics for the MCTD patients with and without inter-
stitial lung disease are presented in Table I. 
Mild leukopenia (i.e. < 4000/μl and > 2500/μl) 
was the most common (33.3%) complete blood 
count finding. Besides the obligatory presence of 
anti-RNP autoantibodies, the most common auto-
antibodies were anti-SSA (43.3%) and anti-dsDNA 
(33.3%) (Table I). Anti-Ro52 antibodies were de-
tected only in 1 (3.33%) patient. Antiphospho-
lipid antibodies were not assessed routinely in 
our group of patients as no one had a history of 
thrombotic or obstetrical complications.
Almost one-fifth of patients had giant capillar-
ies confirmed in NFC. 
Hand oedema, sclerodactyly and the presence 
of giant capillaries in NFC correlated significantly 
with the risk of interstitial lung disease (Table II). 
No such correlation was observed for anti-Ro52 
antibodies (data not shown). In a multivariate 
analysis, giant capillaries were identified to inde-
pendently correlate with pulmonary fibrosis (R2 = 
0.82, p < 0.0000001). 
Of the 30 patients, 16 did not require any 
treatment. The remaining patients most common-
ly took methotrexate and hydroxychloroquine 
(23.3% and 20%, respectively). Of the six individ-
uals with lung fibrosis, four received therapy (cy-
clophosphamide in three cases and azathioprine 
in 1 case). 
Discussion
Interstitial lung disease (ILD) in MCTD may 
affect as many as 50% of patients [2, 3]. It im-
pairs pulmonary function and overall physical 
capacity leading to increased morbidity and mor-
tality. The HRCT is a  valuable diagnostic tool for 
detection of lung fibrosis. A non-invasive marker 
predictive of lung involvement would be useful as 
an early warning of possible pulmonary fibrosis. 
Such a test would also help to calculate pre-test 
probability as an indication to perform HRCT. In 
consequence, it may help to start an appropriate 
treatment in patients who are more likely to ben-
efit from earlier initiation of immunosuppressive 
therapy. 
Our data indicate that identification of giant 
capillaries on NFC might be a  promising marker 
heralding early lung involvement in otherwise 
asymptomatic patients. NFC is an easy-to-per-
form non-invasive test. Previously, some distinct 
features of microvascular pathologic alteration 
in NFC were found to be associated with a  par-
ticular connective tissue disease [11]. Moreover, 
investigation of clinical-capillaroscopic alterations 
in patients with systemic sclerosis revealed an as-
sociation with end-organ involvement (including 
lung disease) and rate of disease progression [12].
To the best of our knowledge, only one study 
has examined in detail the relationship between 
NFC findings in MCTD patients and internal organ 
involvement [13]. This study found avascular ar-
eas and reduced capillary density in NFC to be cor-
related significantly with interstitial lung fibrosis 
in patients who had MCTD for a mean of 8.5 years. 
Moreover, during a 3-year follow-up, the dynamic 
nature of capillary changes in MCTD was shown. 
In some patients, immunosuppressive treatment 
presumably resulted in normalization of reduced 
capillary density and in improvement of avascular 
areas that was associated with stabilization or im-
provement of lung disease.
In this study, only patients with MCTD of short 
disease duration (i.e. < 1 year) were enrolled. 
None of the studied individuals had avascular 
areas in NFC examination and HRCT scanning 
revealed only abnormalities classified as mild 
fibrosis. Therefore, we can hypothesize that the 
association between giant capillaries in NFC and 
lung fibrosis in our study may represent early en-
dothelial injury, a primary target in this disease. 
Reduced capillary density and avascular areas 
may represent the next stage of disease progres-
sion. This could explain the correlation between 
NFC findings and more advanced lung disease. 
Further studies are needed to confirm these as-
sumptions. 
Further studies are also needed to detect other 
potential markers of disease progression includ-
ing lung involvement. For example, it might be in-
teresting to assess regulatory T-cells CD4+CD25-
FoxP3 (Tregs) that are associated with disease 
activity and organ damage in systemic lupus ery-
thematosus (SLE) [14].
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Our study has several limitations. First, due 
to a small sample size and enrolment of patients 
with relatively short disease duration (i.e. < 1 year), 
our results might not be generalizable to all pa-
tients with MCTD, which comprises a broad clin-
ical spectrum. Second, the study design was 
retrospective and lacked longitudinal follow-up, 
and thus did not allow investigation of the cumu- 
Table II. Predictors of pulmonary fibrosis
Variable OR (95% CI) P-value
Hand oedema 19 (1.8–202) 0.009
Sclerodactyly 34.5 (2.4–506.1) 0.01
Giant capillaries in NFC 179.7 (6.4–5031) 0.0001
OR – odds ratio, NFC – nailfold capillaroscopy.
Table I. Clinical and laboratory characteristics of patients with mixed connective tissue disease (MCTD) with and 
without interstitial lung disease (ILD)





Age (min.–max.) [years] 52.5 (45–62) 46.5 (22–81) NS
Females 6 (100) 21 (87.5) NS
Photosensitivity 5 (83.3) 23 (95.8) NS
Xerophthalmia or xerostomia 0 (0) 4 (16.7) NS
Muscle pain 3 (50) 11 (45.8) NS
Myositis 3 (50) 9 (37.5) NS
Fatigue 2 (33.3) 10 (41.7) NS
Raynaud’s syndrome 5 (83.3) 16 (66.7) NS
Arthralgia 4 (66.7) 15 (62.5) NS
Arthritis 2 (33.3) 6 (25) NS
Oral aphthosis 0 (0) 1 (4.2) NS
Sclerodactyly 4 (66.6) 5 (20.8) 0.04
Hand oedema 5 (83.3) 5 (20.8) 0.01
Facial erythema 2 (33.3) 12 (50) NS
Dysphagia 0 (0) 1 (4.2) NS
Livedo reticularis 0 (0) 5 (20.8) NS
Alopecia 0 (0) 4 (16.7) NS
Leukopenia (< 4000/μl) 3 (50) 7 (29.2) NS
Lymphopenia (< 1000/μl) 2 (33.3) 3 (12.5) NS
Thrombocytopenia  (< 150 000/μl) 0 (0) 2 (8.3) NS
Positive ANA 6 (100) 24 (100) NS
ANA nuclear homogeneous pattern 4 (66.7) 3 (12.5) NS
ANA nuclear speckled pattern 6 (100) 24 (100) NS
ANA nuclear centromere pattern 0 (0) 0 (0) NS
ANA nucleolar pattern 0 (0) 1 (4.2) NS
ANA cytoplasmic pattern 3 (50) 8 (33.3) NS
Anti-ds-DNA 4 (66.7) 6 (25) NS
Anti-SSA 3 (50) 10 (41.7) NS
Anti-SSB 0 (0) 1 (4.2) NS
Anti-Sm 0 (0) 2 (8.3) NS
Avascular areas in NFC 0 (0) 0 (0) NS
Giant capillaries in NFC 5 (83.3) 0 (0) 0.0001
Variables are shown as number (percentage) or otherwise stated. ANA – antinuclear antibodies, NFC – nailfold capillaroscopy.
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lative incidence of each clinical manifestation and 
their progression. Third, the age range of our pa-
tients was large (22–81 years). One may note that 
aging patients are more prone to autoimmune re-
actions. The mechanism and pathophysiology of 
autoimmunity seem to be different in this group 
of patients as in younger ones. However, only 
two of the included patients were at the age of 
≥ 65 years, the median age was 48 years, and the 
group was otherwise clinically homogeneous. Fi-
nally, due to the lack of quantification of capillary 
alterations and scoring systems, NFC remains an 
operator-dependent examination. 
In conclusion, this study points to an import-
ant role for NFC in the detection of lung involve-
ment in patients with MCTD. NFC should be per-
formed in all patients with MCTD. The enlarged 
capillaries in NFC may serve as an early marker 
of lung fibrosis in a subgroup of individuals with 
a diagnosis of MCTD of less than 1 year’s dura-
tion. These findings need confirmation in other 
studies, preferably in patients with different du-
rations of disease and various stages of intersti-
tial lung disease. 
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